News
RNXT
1.715
+2.69%
0.045
Weekly Report: what happened at RNXT last week (0914-0918)?
Weekly Report · 1d ago
Weekly Report: what happened at RNXT last week (0907-0911)?
Weekly Report · 09/14 10:29
Weekly Report: what happened at RNXT last week (0831-0904)?
Weekly Report · 09/07 10:22
These low-priced stocks are flashing overbought signals
Seeking Alpha · 09/04 16:19
The best Quant-rated stocks trading below $10 right now
Seeking Alpha · 09/04 10:51
6 Biotech Stocks To Watch Ahead Of Key Catalysts: RenovoRx, Eupraxia, Connect Bio, Kardigan & More
NASDAQ · 09/03 03:20
Biotech Stocks At 52-Week Highs - RNXT +15%, EOLS, CRNX, APGE
NASDAQ · 09/01 07:46
Weekly Report: what happened at RNXT last week (0824-0828)?
Weekly Report · 08/31 10:30
Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI
NASDAQ · 08/31 09:01
Weekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal
NASDAQ · 08/28 14:42
RenovoRx Price Target Raised to $14.50/Share From $14.00 by Ascendiant Capital
Dow Jones · 08/28 11:00
RenovoRx Is Maintained at Buy by Ascendiant Capital
Dow Jones · 08/28 11:00
RenovoRx price target raised to $14.50 from $14 at Ascendiant
TipRanks · 08/28 10:55
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5
Benzinga · 08/28 10:50
RenovoRx Publishes Positive PK/PD Data For RenovoCath In Drug Delivery To Tumors; Stock Up
NASDAQ · 08/26 07:02
Tuesday Sector Leaders: Metals & Mining, Biotechnology Stocks
NASDAQ · 08/25 17:52
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 08/25 17:06
RenovoRx Announces Publication Of Sub-Study Data From Its Ongoing Phase III TIGeR-PaC Clinical Trial In The Journal Cancer Chemotherapy And Pharmacology; Data Show Trans-Arterial Micro-Perfusion-Mediated Delivery Concentrated Chemotherapy At The Tumor Site, Extracting ~51% Of Drug Locally Before It Entered The Bloodstream, Meaningfully Lowering Systemic Exposure
Benzinga · 08/25 12:36
RenovoRx publishes pharmacokinetic, pharmacodynamic data from TIGeR-PaC trial
TipRanks · 08/25 12:35
Weekly Report: what happened at RNXT last week (0817-0821)?
Weekly Report · 08/24 10:31
More
Webull provides a variety of real-time RNXT stock news. You can receive the latest news about Renovorx Inc through multiple platforms. This information may help you make smarter investment decisions.
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.